Shares of computer hardware and IT solutions company Dell (NYSE:DELL) jumped 2.9% in the afternoon session after analyst firm Barclays upgraded its rating on the stock to Overweight from Equal Weight, pointing to strong orders for the company's Artificial Intelligence (AI) servers.
Shares of work management platform monday.com (NASDAQ:MNDY) jumped 4.3% in the afternoon session after positive analyst ratings affirmed confidence in the company's outlook.
Shares of solar tracking systems manufacturer Array (NASDAQ:ARRY)
jumped 5.6% in the afternoon session after Barclays raised its price target on the stock from $8.00 to $9.00.
Shares of electronic component provider Littelfuse (NASDAQ:LFUS) jumped 5.2% in the afternoon session after the stock rallied amid broad strength in the semiconductor sector, driven by a positive industry growth forecast.
Shares of electricity storage and software provider Fluence (NASDAQ:FLNC)
jumped 11.3% in the afternoon session after the company announced it would supply its advanced energy storage solution for the 1,200 MWh Pioneer Clean Energy Center project in Arizona.
Shares of glass and electronic component manufacturer Corning (NYSE:GLW) jumped 3.8% in the afternoon session after BofA raised its price target on the company's shares to $110 from $95 while keeping a Buy rating.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 12.1% in the afternoon session after the company agreed to be acquired by Boston Scientific in a deal valued at approximately $14.5 billion.
Shares of aircraft leasing company FTAI Aviation (NASDAQ:FTAI) jumped 6.5% in the afternoon session after it hit a record all-time high, driven by intense investor interest in its newly unveiled FTAI Power initiative.
Shares of online home goods retailer Wayfair (NYSE:W)
jumped 2.9% in the afternoon session after the company announced its role as a foundational partner in the development of Google's Universal Commerce Protocol, a new standard for AI-driven shopping.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 4.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) delayed its decision on the company's new oral weight-loss pill, Orforglipron. The regulator pushed its decision date to April 10 from a prior expectation of late-March. Markets often react negatively to such postponements as they delay a product's market launch and extend uncertainty over its potential sales, which can limit revenue growth. The drug was part of the administration's fast-track review program, which promised quicker decisions for medicines considered critical to public health.
